Aktienanalyse zu Champions Oncology Inc (CSBR)CSBRChampions Oncology Inc

Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions (TOS). This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

CSBR is not a strong buy at the moment due to its current price of $4.93, which is significantly lower than its 200-day moving average of $6.13, indicating a bearish trend. The RSI is at 40.16, suggesting the stock is nearing oversold territory but not yet a clear buy signal. Additionally, the forward P/E ratio of 22.88 indicates that the stock may be overvalued based on future earnings expectations. The main risk is the declining net income, with a reported net income of -667,000 USD in Q4 2026, reflecting ongoing profitability challenges.

1 analysts cover CSBR: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 12.00.